<DOC>
	<DOCNO>NCT00089037</DOCNO>
	<brief_summary>RATIONALE : Sirolimus , tacrolimus , methotrexate may effective prevent acute graft-versus-host disease patient undergo donor stem cell transplantation . PURPOSE : This phase I/II trial study side effect sirolimus give together tacrolimus methotrexate see well work prevent acute graft-versus-host disease patient undergo donor stem cell transplantation hematologic cancer .</brief_summary>
	<brief_title>Sirolimus , Tacrolimus , Methotrexate Preventing Acute Graft-Versus-Host Disease Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety efficacy sirolimus administer tacrolimus methotrexate prevention acute graft-versus-host disease ( GVHD ) patient hematological malignancy undergo hematopoietic stem cell transplantation unrelated donor . Secondary - Determine absorption pharmacokinetics sirolimus patient treat regimen . - Correlate sirolimus blood concentration prevention GVHD toxicity patient treated regimen . - Determine severity post-transplantation mucositis patient treat regimen . OUTLINE : This nonrandomized , open-label , pilot study . Patients receive oral sirolimus daily day -3 175 tacrolimus IV continuously begin day -3 continue patient able tolerate food orally twice daily day 175 . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . Treatment continue absence acute graft-vs-host disease unacceptable toxicity . Patients follow 5 year . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hematological malignancy No chronic phase chronic myelogenous leukemia , de novo acute leukemia first remission , myelodysplastic syndrome refractory anemia Scheduled hematopoietic stem cell transplantation unrelated donor Currently receive condition regimen comprise cyclosporine total body radiotherapy ( 1,200 1,350 cGy ) busulfan cyclosporine Donor must type high level resolution One single nonserologic disparity A , B , C alleles allow provided disparity within third fourth digit allele No mismatch DRB1 DQB1 PATIENT CHARACTERISTICS : Age Per primary treatment protocol Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic SGOT SGPT ≤ 2.0 time upper limit normal Bilirubin normal Hepatitis B C virus negative Renal Creatinine clearance ≥ 70 mL/min Cardiovascular No cardiac insufficiency require treatment No coronary artery disease Pulmonary No acute pulmonary infection chest xray No severe hypoxemia pO_2 &lt; 70 mm Hg AND DLCO &lt; 70 % predict No mild hypoxemia pO_2 &lt; 80 mm Hg AND DLCO &lt; 60 % predict Other Not pregnant nursing Negative pregnancy test HIV negative No active systemic infection No known hypersensitivity macrolide antibiotic ( e.g. , erythromycin , azithromycin , clarithromycin ) No prior intolerance unresponsiveness sirolimus PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No concurrent Tcell deplete transplantation Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify Other No concurrent grapefruit juice No concurrent voriconazole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
</DOC>